Clinical Trial Update: A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating AP1189 in patients with idiopathic membranous nephropathy who have nephrotic syndrome or severe proteinuria. The study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Membranous Nephropathy
• Nephrotic Syndrome

Drugs mentioned

• AP1189

Snippet

Sponsor: SynAct Pharma Aps | Conditions: Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy, Severe Proteinuria Due to Idiopathic Membranous Nephropathy | Phase 2 | Status: RECRUITING